Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker.

Thorac Cancer · 2025 · PMC11959145 · PMID 40165604

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

In this study, TP53‐mutant tumors exhibited a trend toward higher TMB compared to TP53 wild‐type tumors, although the difference did not reach statistical significance ( p = 0.066).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.